INTRODUCTION
============

Breast cancers arising in women who inherit heterozygous mutations in *BRCA2* are associated with a high prevalence of genomic alterations and aggressive clinical behavior ([@R1], [@R2]). Because of the high risk of these cancers in *BRCA2* mutation carriers, many such women elect to undergo bilateral mastectomy for breast cancer prevention. However, despite the unmet need for more effective breast cancer prevention approaches in this setting, the stepwise evolution from an otherwise normal *BRCA2* heterozygous mutant (*BRCA2^mut/+^*) cell to an invasive malignancy has not been defined. Homozygous loss of *BRCA2* is embryonically lethal ([@R3]--[@R5]), and acute loss in cultured cells rapidly leads to DNA damage and growth arrest or cell death ([@R6]--[@R8]). These observations suggest a multistep pathogenesis in which homozygous *BRCA2* loss is not the earliest genetic event but rather that the wild-type *BRCA2* allele may remain intact as early genetic changes accumulate. Critically, however, this scenario leaves unresolved the nature and enabling mechanism for early cancer evolution. Haploinsufficiency for *BRCA2* has been proposed as a possible driver of early pathogenesis, but direct evidence for such an effect in the normal human mammary gland is inconsistent. Furthermore, heterozygous genetically engineered mouse models (GEMMs) of *BRCA2* are not tumor prone and therefore represent a poor model of precancerous evolution in this setting ([@R3]--[@R5], [@R8], [@R9]). While the *BRCA1* tumor suppressor shares many of these features ([@R9], [@R10]), the pathogenesis of *BRCA1*- versus *BRCA2*-associated breast cancers may differ in important ways, as the former are primarily hormone receptor (HR) and HER2-negative tumors, while the latter are primarily HR positive ([@R11]).

We sought to unveil the earliest steps in the pathogenesis of *BRCA2*-associated breast tumors through detailed analysis of histologically normal glands from women harboring germline deleterious mutations who elected to undergo bilateral prophylactic mastectomy. Genomic analysis of individual cells revealed frequent polyclonal chromosomal damage, which was most prevalent among the subset of epithelial cells that are the suspected cells of origin of these cancers. Corresponding defects in replication stress and DNA damage checkpoint responses in these same cells collectively define a previously unappreciated phenotype for *BRCA2* that precedes histologic abnormalities in the human breast. The discovery of these precancerous hallmarks paves the way for improving clinical risk prediction and cancer prevention in this population.

RESULTS
=======

Single-cell whole-genome analysis reveals subchromosomal aneuploidy in *BRCA2^mut/+^* human primary breast epithelial cells
---------------------------------------------------------------------------------------------------------------------------

We carried out detailed analysis of noncancerous glands from *BRCA2* carriers who elected to undergo bilateral prophylactic mastectomy, using as control tissues from women matched for age, menopausal status, and hormonal exposure electing cosmetic breast surgery ([Fig. 1A](#F1){ref-type="fig"} and table S1). None of these women had a previous breast cancer diagnosis or chemotherapy exposure, and no occult cancers were detected upon histologic analysis of the tissues we analyzed (table S1). We used established markers to carry out flow cytometry--based isolation and sorting of the three major epithelial cell subpopulations: mature luminal (ML), luminal progenitor (LP), and basal epithelial cells ([Fig. 1A](#F1){ref-type="fig"}). Notably, data from GEMMs and gene expression analyses of human tumors have suggested that the cell of origin of *BRCA1*-associated breast cancer is the LP cell ([@R12], [@R13]), while *BRCA2*-associated tumors may arise from an LP-related cell or a more ML cell ([@R14]).

![Single-cell whole-genome analysis of *BRCA2^mut/+^* human primary breast epithelial cells.\
(**A**) Workflow depicts dissociation and isolation of human breast epithelial cells from *BRCA2* carrier (*BRCA2^mut/+^*) prophylactic mastectomy and control \[wild-type (WT)\] elective mammoplasty cases for subsequent analyses, as indicated. Dot plot at center shows representative flow cytometry sorting via CD49f and EpCAM of ML, LP, and basal epithelial cells. FACS, fluorescence-activated cell sorting. (**B**) Summary of single-cell whole-genome sequencing (WGS) analysis of flow-sorted, primary uncultured breast epithelial cells. Copy number variation (CNV) calls for individual cells (rows) across the genome (*x* axis; Chr, chromosome) are shown, with gains and losses boxed. Cell types and genotypes are indicated at the top left, and individual patient ID numbers are indicated at the right. In total, 252 sequenced breast epithelial cells from *BRCA2^mut/+^* (*n* = 5) and control (*n* = 2) tissue specimens are depicted. (**C**) Bar chart depicting the prevalence of CNVs in LP (L) and basal (B) cells of *BRCA2* carrier and control (WT) patients. Color code depicts the number of CNVs identified per cell. (**D**) LP cells from *BRCA2* carriers are significantly more likely to harbor CNVs than basal cells. *P* value is determined by χ^2^ test.](aay2611-F1){#F1}

Among the earliest events in cancer evolution are thought to be polyclonal somatic genomic alterations. Accordingly, we looked for the presence of somatic copy number variations (CNVs) at high resolution through single-cell whole-genome sequencing (WGS) of uncultured, flow-sorted primary LP and basal epithelial cells from *BRCA2* carriers and controls. Low-coverage WGS provides sufficiently high resolution to identify subchromosomal CNVs as small as 10 Mb, and our methodology for single-cell whole-genome amplification and analysis has been previously validated ([@R15], [@R16]). We carried out WGS to an average depth between 0.1× to 0.05× and then used two independent algorithms (HMMcopy and DNAcopy) to assign and confirm copy number changes across the genome ([@R15], [@R16]). Previous studies using this methodology have demonstrated that in unselected individuals, the proportion of cells with any such CNVs is very low (\<5% of cells) in normal epithelial and brain tissues ([@R16]). In contrast, among nearly 100 individual LP cells from a cohort of *BRCA2* carriers analyzed by WGS, we observed that 27% demonstrated one or more CNVs of \>10 Mb ([Fig. 1, B to D](#F1){ref-type="fig"}). Applying this methodology to an equal number of basal breast epithelial cells from the same individuals also revealed a substantial excess of cells harboring CNVs (13%), although significantly less than the proportion of CNV-positive LP cells (*P* = 0.04) ([Fig. 1, B to D](#F1){ref-type="fig"}). By comparison, a parallel WGS analysis of sorted LP and basal cells from noncarriers revealed a single CNV in 90 cells ([Fig. 1, B and C](#F1){ref-type="fig"}). As further validation of our sequencing and analysis pipelines, we reanalyzed existing data from normal skin and brain cells sequenced on the same platform. The overall sequence quality was comparable between these cells and the breast epithelial cells, and we confirmed the low prevalence of CNV-positive cells in 142 skin and brain cells sequenced (fig. S1). Thus, breast epithelia, and particularly, LP cells from noncancerous breast tissue of *BRCA2* carriers harbor frequent subchromosomal aneuploid events ([Fig. 1D](#F1){ref-type="fig"} and fig. S2A).

One notable CNV we observed was duplication of the entire chromosome 1q arm, which is a common genomic abnormality in breast cancer ([Fig. 2A](#F2){ref-type="fig"}) ([@R17]). Most of the identified CNVs were subchromosomal haploid losses, consistent with the widespread pattern of losses observed in *BRCA2*-associated breast cancer ([Fig. 2A](#F2){ref-type="fig"} and fig. S2B) ([@R1]). In some cases, identical losses were shared between multiple cells of the same patient, a finding that could conceivably correspond to early clonal evolution ([Fig. 2B](#F2){ref-type="fig"}). None of the losses in any cell involved the *BRCA2* locus on chromosome 13 ([Fig. 1B](#F1){ref-type="fig"} and fig. S2, B to E). Previous analyses of germline *BRCA2*-associated breast cancers have demonstrated that most genetic loss-of-heterozygosity (LOH) events for *BRCA2* itself are \>10 Mb and therefore would have been detected by our analysis ([@R18]). This observation suggests that the wild-type *BRCA2* allele is intact in our cases, implying that accumulation of subchromosomal aneuploidy may be a haploinsufficient phenotype. To confirm the integrity of the wild-type allele, we performed targeted polymerase chain reaction (PCR) amplification of the locus surrounding the patient-specific *BRCA2* mutation from individual cells. Although efficiency for detection of either allele was low, we did not observe a bias toward detection of the mutant allele alone in the cells analyzed ([Fig. 2C](#F2){ref-type="fig"} and table S2). Together, these findings imply that subchromosomal aneuploidy is an early and potentially haploinsufficient phenotype in *BRCA2^mut/+^* breast epithelia.

![Polyclonal, subchromosomal aneuploidy is a hallmark of *BRCA2^mut/+^* breast epithelial cells.\
(**A**) Representative segmentation plots of individual LP (*n* = 4) and basal (*n* = 2) cells harboring CNVs from four *BRCA2* mutation carriers. *Y* axis depicts normalized WGS read counts across the genome (*x* axis). Red dots indicate region of gain, whereas blue dots indicate losses. Patient ID numbers are indicated at the right. (**B**) Segmentation plots of three LP cells that share a clonal loss (red box) in a *BRCA2* carrier (patient 131). Zoomed-in images of the clonal loss are shown at the right. (**C**) Representative chromatograms from single-cell PCR-based Sanger sequencing of genomic DNA in a *BRCA2^mut/+^* LP cell. The presence of a heterozygous single-nucleotide polymorphism (SNP) and the superimposition of sequences adjacent to the frameshift mutation suggest that LOH has not occurred.](aay2611-F2){#F2}

*BRCA2^mut/+^* primary cells exhibit DNA damage and a deregulated replication stress response
---------------------------------------------------------------------------------------------

The presence of viable aneuploid cells in *BRCA2^mut/+^* tissues suggested ongoing DNA damage and/or a deregulated stress/damage response. Thus, we next used an independent method to directly assess DNA damage in single cells, the comet assay. This assay uses cells embedded in agarose that are lysed and then subjected to electrophoresis, causing broken DNA structures to migrate toward the anode, thus forming a comet tail ([@R19]). We briefly cultured freshly collected cells from *BRCA2* carriers or controls under ultralow attachment conditions (48 to 72 hours) to select for epithelial progenitor cells before plating ([@R20]). Consistently, cells from *BRCA2* carriers demonstrated increased DNA breaks at baseline compared to controls ([Fig. 3A](#F3){ref-type="fig"}). In addition, inducing replication stress by treatment with hydroxyurea (HU) led to further increases in DNA damage in *BRCA2^mut/+^* cells, potentially reflecting the established role of *BRCA2* in protection of stalled replication forks ([Fig. 3A](#F3){ref-type="fig"}) ([@R21]).

![*BRCA2^mut/+^* breast epithelial cells exhibit DNA damage and an impaired replication stress checkpoint response.\
(**A**) Representative images of comet assays performed on primary human breast epithelial cells isolated from control (WT) and *BRCA2^mut/+^* tissues. Red lines highlight "tail" of broken DNA. Graph below summarizes data from *n* = 3 patients per genotype (50 cells per patient). Cells were either untreated (Unt) or treated with HU for 4 hours. Data are depicted as fold change in tail DNA intensity. *P* values are determined by unpaired *t* test. \*\*\**P* \< 0.001 and \*\*\*\**P* \< 0.0001. Error bars indicate SD. (**B**) Representative confocal immunofluorescence staining of primary breast epithelial cells for p-CHEK1 (Ser^317^) shows increased nuclear staining following HU treatment only in control (WT) but not in *BRCA2^mut/+^* cells. Graph at the right summarizes nuclear fluorescence of individual cells (dots) (*n* = 4 patients for control and n = 3 patients for *BRCA2^mut/+^*; four fields counted per condition per patient). *P* values are determined by unpaired *t* test. \*\*\**P* \< 0.001 and \*\*\*\**P* \< 0.0001. Horizontal lines indicate means and SDs. Scale bars, 20 μm. (**C**) Chromatograms depicting Sanger DNA sequencing of a cytospin of primary breast cells assayed in (B) from a *BRCA2^mut/+^* patient harboring *BRCA2* 5799_5802delCCAA (p.Asn1933Lysfs). The superimposition of sequences adjacent to the frameshift mutation suggests that LOH has not occurred. (**D**) Heat map of RNA sequencing (RNA-seq) data from freshly sorted cells shows differential expression of RSRD (replication stress response deficiency) genes ([@R24]) in *BRCA2^mut/+^* LP cells (*n* = 7 patients) compared to control (WT) LP cells (*n* = 9 patients). Columns correspond to individual patients.](aay2611-F3){#F3}

We then examined the response to this genomic stress by analyzing phosphorylation of CHEK1, a central coordinator of the response to replication stress and DNA damage ([@R22], [@R23]). Cytospins of primary epithelial progenitor cultures prepared as above were stained for phosphorylated CHEK1 at baseline or following 4 hours of exposure to HU. As anticipated, control primary epithelia exhibited increased CHEK1 phosphorylation within 4 hours of HU treatment ([Fig. 3B](#F3){ref-type="fig"}). In contrast, however, cells from *BRCA2* carriers exhibited a failure to activate CHEK1 in response to HU, despite normal levels of total CHEK1 protein ([Fig. 3B](#F3){ref-type="fig"} and fig. S3A). DNA sequencing of these cells revealed the presence of both wild-type and mutant *BRCA2* alleles ([Fig. 3C](#F3){ref-type="fig"}). These findings provide further support for a haploinsufficient phenotype of *BRCA2* in the response to genomic stress.

Because we observed a deregulated genomic stress response in vitro, we wanted to know whether this also occurs in vivo. Thus, we carried out RNA sequencing (RNA-seq) analysis of freshly sorted LP and basal epithelial cell populations from *BRCA2* carrier tissues or controls ([Fig. 1A](#F1){ref-type="fig"}). Analysis of these data revealed enrichment in *BRCA2^mut/+^* LP cells of an established signature reflecting a failure of the ATR (Ataxia telangiectasia mutated and Rad3-related)/CHEK1 (checkpoint kinase 1)--mediated replication stress checkpoint in nontransformed mammary epithelial cells ([Fig. 3D](#F3){ref-type="fig"} and fig. S3B) ([@R24]). This replication stress response deficiency signature is known to predict future cancer risk ([@R24]), and it contains some of the top most differentially expressed genes between *BRCA2^mut/+^* and control LP cells ([Fig. 3D](#F3){ref-type="fig"}). Among these are genes of potential relevance to HR-positive breast cancer (which comprise 80% of *BRCA2*-associated breast cancers), including the estrogen receptor target gene *HOXC4* and the GATA transcription factor--binding partner gene *ZFPM1* ([Fig. 3D](#F3){ref-type="fig"}) ([@R25], [@R26]). Furthermore, evaluation of differentially expressed programs through gene set enrichment analysis (GSEA) revealed the highly significant deregulation of a radiation response signature in *BRCA2^mut/+^* LP cells (fig. S3C) ([@R27]). Notably, the differential expression of this signature between *BRCA2^mut/+^* and control cells was far more significant within the LP compared to the basal population, in keeping with the more frequent occurrence of CNVs among LP cells (fig. S3C). Again, consistent with haploinsufficiency for *BRCA2*, the RNA-seq data showed no evidence for exclusive expression of the mutant allele in *BRCA2^mut/+^* LP cells (fig. S3D). Thus, *BRCA2^mut/+^* LP cells exhibit evidence of aberrant replication stress and DNA damage responses in vivo.

*BRCA2^mut/+^* LP cells show increased TP53 activity and decreased NF-κB/SASP pathway expression
------------------------------------------------------------------------------------------------

We then turned to examine the downstream consequences of the DNA damage detected in LP cells of *BRCA2* carriers. A hallmark genetic event that cooperates with *BRCA2* deficiency in cancer pathogenesis is loss of *TP53*, suggesting that activation of TP53 may be an early barrier to malignant progression in this setting ([@R28]). We therefore hypothesized that the failed CHEK1-dependent replication stress response we observed might ultimately lead to DNA double-strand breaks and thereby trigger TP53 activation through a CHEK1-independent pathway ([@R29]). Recent studies suggest that CHEK1 is not required for TP53 activation in primary breast epithelial cells following DNA damage ([@R30]). RNA-seq analysis did suggest activation of TP53 in *BRCA2^mut/+^* LP cells, evidenced by the increased expression of multiple direct TP53 target genes ([Fig. 4A](#F4){ref-type="fig"}) ([@R31], [@R32]). This in vivo effect was associated with a strong transcriptional profile indicating suppression of nuclear factor κB (NF-κB) signaling, including numerous cytokine and inflammatory factors associated with the senescence-associated secretory phenotype (SASP) ([Fig. 4, B to D](#F4){ref-type="fig"}). TP53 is known to suppress the NF-κB/SASP response ([@R33], [@R34]), and this effect is emerging as a relevant component of TP53-dependent tumor suppression given that accumulation of SASP-expressing cells is an established driver of tumorigenesis ([@R35]). We independently validated the corresponding alterations in NF-κB protein expression, demonstrating that the NFKB1 (p50) and NFKB2 (p52) subunits were expressed at lower levels in *BRCA2* carrier tissues compared to controls ([Fig. 4C](#F4){ref-type="fig"}). Furthermore, knockdown of *BRCA2* in nontransformed mammary epithelial cells via lentiviral short hairpin RNA attenuated expression of the same cytokine and NF-κB target genes that were down-regulated in *BRCA2^mut/+^* progenitor cells in vivo (fig. S4A). Similar to the damage response signature (fig. S3C), deregulation of the SASP program was selective for LP cells in *BRCA2* carriers, as no significant suppression of SASP was observed in the corresponding basal epithelial cells of these same patients (fig. S4B). These results suggest that DNA damage and TP53 activation in *BRCA2^mut/+^* LP cells are associated with suppression of the NF-κB/SASP response.

![*BRCA2^mut/+^* LP cells display increased TP53 activity and suppressed NF-κB/SASP pathway expression.\
(**A**) Bar charts show the mean expression levels of canonical TP53 target genes in freshly sorted *BRCA2* carrier LP cells (*n* = 7 patients) compared to controls (WT; *n* = 9 patients), assessed by RNA-seq. Error bars denote SEM. *P* values are determined by Mann-Whitney test. \**P* \< 0.05 and \*\**P* \< 0.01. XPC, Xeroderma pigmentosum group C-complementing protein; FPKM, Fragments Per Kilobase of transcript per Million mapped reads. (**B**) Heat map depicts down-regulation of NF-κB/SASP pathway genes in *BRCA2* carrier LP cells compared to controls (WT), assessed by RNA-seq as in (A). Columns correspond to individual patients. Direct NF-κB target genes are highlighted in red. (**C**) Western blot analysis shows that NFKB1 (p50) and NFKB2 (p52) subunits are expressed at lower levels in *BRCA2^mut/+^* breast tissues compared to control (WT) tissues (*n* = 3 patients per genotype). β-Tubulin serves as a loading control. (**D**) Negative enrichment of a SASP signature in GSEA of RNA-seq data from freshly sorted LP cells of *BRCA2* carriers (*n* = 7 patients) and controls (WT; *n* = 9 patients). NES, normalized enrichment score; FDR, false discovery rate.](aay2611-F4){#F4}

Age-associated deregulation of breast epithelial cell proportions in *BRCA2* carriers suggests expansion of a damaged LP cell population over time
--------------------------------------------------------------------------------------------------------------------------------------------------

Deregulated DNA damage and senescence/SASP responses in *BRCA2* LP cells might be expected to alter the proportion of these cells over time ([@R36]). We thus sought to address whether there were differences in the proportions of progenitor or other epithelial subpopulations in *BRCA2^mut/+^* tissues compared to controls. We collected a larger cohort of tissues from *BRCA2* carriers (*n* = 26) and controls (*n* = 28), then performed flow cytometric analysis on these specimens, and plotted the proportions of each epithelial subpopulation as a function of age for each cohort ([Fig. 5A](#F5){ref-type="fig"}). In noncarrier controls, no significant age-associated changes in the prevalence of these subpopulations were noted. In contrast, *BRCA2* carriers showed an age-associated expansion in the proportion of LP cells and a decline in the basal cell fraction ([Fig. 5B](#F5){ref-type="fig"} and fig. S5, A and B). These differences were not accounted for by demographic factors such as parity or menopausal status, as these factors were not associated with significant differences in epithelial cell proportions (fig. S5, C and D). Thus, DNA damage and suppression of a senescence-associated program in *BRCA2^mut/+^* LP cells are accompanied by an age-associated expansion of this progenitor cell compartment ([@R36]).

![Noncancerous breast tissues of *BRCA2* mutation carriers demonstrate age-associated deregulation of epithelial cell proportions compared to controls.\
(**A**) Representative flow cytometry analysis showing distinct epithelial subpopulations (basal, LP, and ML) isolated from breast tissues of control (WT) and *BRCA2* mutation carriers following sorting via CD49f and EpCAM staining. Numbers indicate percentages of each epithelial cell subpopulation. (**B**) Linear regression analysis of LP and basal cell proportions by age for controls (WT) (*n* = 26 patients) and *BRCA2* carriers (*n* = 28 patients). The LP/basal ratio by patient provides additional validation as it accounts for technical factors that may have subtle effects on absolute cell numbers. (**C**) TUNEL (terminal deoxynucleotidyl transferase--mediated deoxyuridine triphosphate nick end labeling) staining of representative control (WT) and *BRCA2* carrier tissues. Summary data obtained by counting four fields for five patients per genotype are shown. \*\*\*\**P* \< 0.0001 by Fisher's exact test.](aay2611-F5){#F5}

Last, we hypothesized that altered epithelial cell proportions and a deregulated NF-κB/SASP program in *BRCA2* carrier tissues may be associated with differences in cell proliferation and/or survival in vivo ([@R36]). We did not observe strong differences in proliferation assessed by Ki67 staining between these *BRCA2* carrier breast tissues and controls, prompting us to ask whether differences in cell survival might contribute to the age-associated expansion of the LP population in this context. We therefore carried out TUNEL (terminal deoxynucleotidyl transferase--mediated deoxyuridine triphosphate nick end labeling) staining, an established marker of apoptosis, in *BRCA2* carrier tissues and controls. The proportion of TUNEL-positive cells is well documented in normal human breast epithelial tissues, and we observed a similar prevalence of these cells in the control tissues we tested ([Fig. 5C](#F5){ref-type="fig"}) ([@R37]). In contrast, however, *BRCA2* mutation carrier tissues consistently showed a paucity of TUNEL-positive luminal epithelial cells across all patients tested, in keeping with established links between checkpoint and NF-κB suppression and a defective apoptotic response ([Fig. 5C](#F5){ref-type="fig"}) ([@R38], [@R39]). Collectively, our findings suggest that noncancerous *BRCA2^mut/+^* breast tissues exhibit *BRCA2* haploinsufficiency and an age-associated accumulation of DNA-damaged luminal epithelial progenitor cells bearing altered checkpoint and survival responses ([Fig. 6](#F6){ref-type="fig"}).

![Summary of findings in primary *BRCA2^mut/+^* breast tissues.\
Epithelial progenitor cells of heterozygous germline *BRCA2* carriers exhibit DNA damage, failed replication stress, and damage responses, together with attenuated apoptosis. LOH analyses suggest that these findings may reflect a haploinsufficient phenotype for *BRCA2* in vivo.](aay2611-F6){#F6}

DISCUSSION
==========

This study advances our understanding of early changes in *BRCA2^mut/+^* breast tissues, defining unanticipated phenotypes in this setting with implications for both cancer risk assessment and prevention. Most of the tissues we studied were deemed to be histologically normal by highly experienced breast pathologists, suggesting that the alterations we report precede clinically defined cellular abnormalities (tables S1 and S3). We present evidence that a failed replication stress response and DNA damage in *BRCA2^mut/+^* tissues result from haploinsufficiency for *BRCA2* rather than homozygous loss of function. While the presence of haploinsufficiency for either *BRCA1* or *BRCA2* in vivo has been controversial, our findings are in accord with data suggesting that LOH for the wild-type *BRCA2* is not universal in *BRCA2*-associated cancers ([@R40]). Our observations are also in keeping with a recent report that the BRCA2 protein is selectively susceptible to degradation by environmental aldehydes ([@R41]), an effect that could contribute to a haploinsufficient phenotype in cells with only one functional *BRCA2* allele. Nonetheless, we analyzed a relatively small number of cells and tissues, and it is difficult to definitively rule out LOH in a subset of cells. Thus, our study suggests, rather than confirms, haploinsufficiency for *BRCA2* as a potential initiating event for these cancers.

A prominent feature of the phenotype we have uncovered is frequent subchromosomal aneuploidy, most prevalent within the LP cell population. LP cells are a potential target cell for *BRCA2*-associated carcinogenesis in the breast, and indeed we observe instances of apparently clonally related genomic alterations among these cells. While our study does not prove that they are direct cancer precursors, these alterations could conceivably represent the earliest somatic genetic abnormalities that underlie these malignancies. Notably, all the CNVs we identified were subchromosomal and therefore are to be distinguished from whole-chromosome gains and losses that are typically later events and associated with TP53 inactivation ([@R42]).

Although the early genomic changes we observed are likely to include many passenger events, they, nevertheless, may provide a quantifiable hallmark of the preneoplastic *BRCA2* carrier state. Tracking the prevalence of DNA-damaged cells in the clinical setting could possibly improve risk prediction for these women, who are faced with the difficult choice of whether to undergo mastectomy long before cancer develops. Last, the *BRCA2* haploinsufficient phenotype we report may portend particular vulnerabilities of certain *BRCA2^mut/+^* cancer precursor cells. Accordingly, this work provides a foundation for future studies seeking to identify improved pharmacologic approaches to cancer prevention in this setting.

MATERIALS AND METHODS
=====================

Human breast tissues
--------------------

Fresh human breast tissues were obtained from the Massachusetts General Hospital with approval by the local Institutional Review Board and signed informed patient consent (protocols 93-085 and 2008-P-1789). Samples were either normal breast tissues from reduction mammoplasties (confirmed by pathology) or noncancerous breast tissues from prophylactic mastectomies of known BRCA1 or BRCA2 mutation carriers. All BRCA1/2 carrier status was determined through clinical germline genetic testing performed by commercial providers before tissue collection.

Mammary cell preparations
-------------------------

Tissue samples were minced and digested with collagenase/hyaluronidase (STEMCELL Technologies) in complete EpiCult-B medium supplemented with hydrocortisone (0.48 μg/ml; STEMCELL Technologies) overnight at 37°C. The resulting suspensions were either cryopreserved or further sequentially digested with 0.25% trypsin, dispase (5 mg/ml), and deoxyribonuclease I (1 mg/ml). Single-cell suspensions were collected by filtration through a 40-μm cell strainer.

Cell staining and sorting
-------------------------

Cells were blocked with rat immunoglobulin (Jackson ImmunoLabs) and antibody to Fc receptor--binding inhibitor (eBioscience) before incubation with the following primary antibodies: phycoerythrin (PE)--conjugated anti-human CD31 (BD Pharmingen), PE-conjugated anti-human CD45 (BD Pharmingen), PE-conjugated anti-human CD235a (BD Pharmingen), BV650-conjugated anti-human epithelial cell adhesion molecule (EpCAM) CD326 (BioLegend), and biotin-conjugated anti-human ITGA6 (eBioscience). Where required, cells were incubated with allophycocyanin-Cy7--conjugated streptavidin (BD Pharmingen). Cells were either stained with 4′,6-diamidino-2-phenylindole (DAPI) for viability or fixed with 1% paraformaldehyde and stained with the Zombie Aqua Fixable Viability Kit (BioLegend). Viable cells were sorted on a FACSAria flow cytometer (Becton Dickinson). Data were analyzed using FlowJo software (Tree Star).

Single-cell PCR for allele-specific LOH analysis
------------------------------------------------

Microaspirated single cells were transferred into PCR tubes containing lysis buffer \[water + proteinase K (400 ng/μl) + 17 μM SDS\], and DNA was amplified by nested PCR using primers flanking BRCA2 mutations. Sanger sequencing was performed by the Center for Computational and Integrative Biology DNA Core Facility at the Massachusetts General Hospital.

Primer sequences for patient 128 (Val3079PhefsX4) are as follows: first PCR, TGGCGTCCATCATCAGATTT (forward) and TCAGAGGTTCAAAGAGGCTTAC (reverse); second PCR, CAGATTTACCAGCCACGGGA (forward) and GCCAACTGGTAGCTCCAACTAA (reverse). Primer sequences for patient 140 (6027del4) are as follows: first PCR, GGGCCACCTGCATTTAGGAT (forward) and TGAGCTGGTCTGAATGTTCGT (reverse); second PCR, GCAGGTTGTTACGAGGCATT (forward) and CCTGGACAGATTTTCCACTTGC (reverse).

Comet assays
------------

Single-cell suspensions from patient samples were plated in ultralow adherence plates in Dulbecco's modified Eagle's medium/F12 medium containing insulin (5 μg/ml), epidermal growth factor (10 ng/ml), basic fibroblast growth factor (5 ng/ml), heparin (4 μg/ml), hydrocortisone (500 ng/ml), B27, GlutaMAX, and penicillin-streptomycin. Cells were either treated with HU (10 mM; Sigma) for 4 hours or left untreated and washed with phosphate-buffered saline (PBS), and alkaline comet assays were performed using a Trevigen Comet Assay kit according to the manufacturer's instructions. Olive tail movement was quantified with ImageJ, and 50 individual cells were quantified per condition.

Immunostaining
--------------

Immunofluorescence for paraffin sections and TUNEL staining were performed by Dana-Farber/Harvard Cancer Center Specialized Histopathology Core. For immunofluorescence in cells, fixation was performed with methanol for 10 min, followed by permeabilization in 0.1% Triton X-100 for 2 min. Blocking was performed with 10% horse serum for 30 min, and cells were further incubated with primary p-CHEK1 antibody (Novus Biologicals) for 2 hours, washed with wash buffer (PBS + 10% horse serum + 0.1% Triton X-100), incubated with appropriate secondary antibody for 1 hour, and stained with DAPI. All immunofluorescence images were captured by a confocal microscope (Leica TCS SP8) and were analyzed by ImageJ.

Western blotting
----------------

Snap-frozen tissues were homogenized using Precellys 24 homogenizer (Bertin Technologies). For total protein extraction, cells were lysed in radioimmunoprecipitation assay buffer \[10 mM tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, 0.1% (w/v) SDS, 1% (v/v) NP-40, proteinase inhibitor cocktail, and phosphatase inhibitor cocktail\] for 30 min on ice. Western blotting was performed using NFKB1 p50 (Santa Cruz Biotechnology) and NFKB2 p52 (Millipore) antibodies by standard protocol.

Single-cell copy number analysis
--------------------------------

Fresh tissues were dissociated as described above, and single cells were isolated by microaspiration. Genomic DNA was amplified and sequenced as described in ([@R16]). Fastqs were aligned using bwa-mem, with resulting bams sorted and duplicates marked using Picard. Coverage was then computed over 500-kb bins across the entire genome. The count for each bin was then divided by the sum across all bins for the relative sample (to correct for library size) and then by the median for that genomic bin across all samples from the same batch. The coverage profiles were then transformed into .wig files and fed into the R package HMMcopy for segmentation and CNV calling. HMMCopy was run with *e* = 0.9999999 and nu = 5, with all other parameters set to default. A noise statistic termed "VS" was computed in the same manner as ([@R16]), with cells with values greater than or equal to 0.5 being excluded from the analysis. CNVs that mapped to the Y chromosome were less than 10 Mb in size or had an absolute log~2~ ratio of less than 0.4 that were excluded from the analysis.

RNA-seq analysis
----------------

Total RNA from sorted cell populations was extracted using an RNeasy FFPE kit according to the manufacturer's instructions. Libraries for ribosomally reduced RNA were prepared by the Harvard Biopolymers Facility using directional RNA-seq Wafergen protocol. Libraries were sequenced on Illumina HiSeq 2000 at Next-Generation Sequencing Core at Massachusetts General Hospital. Transcripts per million (TPM) values were computed using Salmon and batch-corrected using ComBat. The two samples with the lowest total counts were excluded from the analysis. GSEA was run on the ComBat-corrected TPM values using phenotype permutation and default parameters. The heat maps in [Fig. 4 (B and D)](#F4){ref-type="fig"} were made using the ComBat-corrected TPM values, subset to the comparison of interest, and transformed into *z* scores by gene.

Other statistical methods
-------------------------

*P* values were determined using Student's unpaired *t* test, unless indicated otherwise.
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